{'fraction_non_alphanumeric': 0.013717421124828532, 'fraction_numerical': 0.0, 'mean_word_length': 5.9523809523809526, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement

Abstract The comprehensive management of patients with fibrotic interstitial lung disease (ILD) is multi-faceted and may include pharmacological and non-pharmacological therapies. There are no current recommendations and few resources to guide the management of patients with fibrotic ILD in Canada. This position statement provides recommendations for the management of patients with fibrotic ILD based on review of the scientific literature and consensus from a panel of ILD experts. These recommendations relate to important clinically relevant questions, and key messages are provided to guide clinical practice.